REGISTERED
on 24 Sep 2024
Last Applicant/ Owned by
F-75011 Paris
FR
Serial Number
79385572 filed on 30th Oct 2023
Registration Number
7510573 registered on 24th Sep 2024
Correspondent Address
Heather Smith-Carra
Filing Basis
1. filing basis filed as 66 a
Disclaimer
NO DATA
CUIVRACEPT
Pharmaceutical products for the treatment of Wilson's disease; pharmaceutical preparations for the treatment of Wilson's disease; medicines for the treatment of Wilson's disease; chemical preparations for medical or pharmaceutical use for the treatment of Wilson's disease; pharmaceutical products in the nature of pharmaceutical preparations and medicines for the treatment of Wilson's disease
Classification Information
Class [005]
Pharmaceutical Products
Pharmaceutical products for the treatment of Wilson's disease; pharmaceutical preparations for the treatment of Wilson's disease; medicines for the treatment of Wilson's disease; chemical preparations for medical or pharmaceutical use for the treatment of Wilson's disease; pharmaceutical products in the nature of pharmaceutical preparations and medicines for the treatment of Wilson's disease
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 79385572
Mark Type
No Service/Collective Mark
Attorney Docket Number
No 008219.00204
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
Yes
66A Current
Yes
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 24th Sep 2024 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| 24th Sep 2024 | REGISTERED-PRINCIPAL REGISTER |
| 09th Jul 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 09th Jul 2024 | PUBLISHED FOR OPPOSITION |
| 19th Jun 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 03rd Jun 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 23rd May 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| 23rd May 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 23rd May 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 19th Mar 2024 | REFUSAL PROCESSED BY IB |